{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:59:55Z","timestamp":1783490395147,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clinthera.2022.07.006","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T08:01:15Z","timestamp":1660204875000},"page":"1178-1186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial"],"prefix":"10.1016","volume":"44","author":[{"given":"Gail L.","family":"Torkildsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad R.","family":"Pattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Jerkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Striffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Nau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.07.006_bib0001","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II Definition and Classification Report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0002","article-title":"2020 Dry Eye Products Market Report: A Global Analysis for 2019 to 2025","author":"Scope","year":"2020","journal-title":"Ophthalmic Comprehensive Reports"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0003","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archophthalmol.2009.103","article-title":"Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies","volume":"127","author":"Schaumberg","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0004","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0002-9394(03)00218-6","article-title":"Prevalence of dry eye syndrome among US women","volume":"136","author":"Schaumberg","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0005","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"issue":"9","key":"10.1016\/j.clinthera.2022.07.006_bib0006","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3390\/jcm8091439","article-title":"Dry Eye Disease: Emerging Approaches to Disease Analysis and Therapy","volume":"8","author":"Heidari","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0007","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4103\/0974-620X.83653","article-title":"A review on recent advances in dry eye: Pathogenesis and management","volume":"4","author":"Bhavsar","year":"2011","journal-title":"Oman J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0008","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II Management and Therapy Report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0009","first-page":"795","article-title":"A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease","volume":"10","author":"Friedman","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/chemse\/25.1.61","article-title":"Evidence for nicotinic acetylcholine receptors on nasal trigeminal nerve endings of the rat","volume":"25","author":"Alimohammadi","year":"2000","journal-title":"Chem Senses"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0011","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1523\/JNEUROSCI.16-24-07892.1996","article-title":"Neuronal nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion: demonstration of alpha3beta4, a novel subtype in the mammalian nervous system","volume":"16","author":"Flores","year":"1996","journal-title":"J Neurosci"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0012","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.preteyeres.2009.04.003","article-title":"Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases","volume":"28","author":"Dartt","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0013","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajo.2017.03.002","article-title":"Randomized Controlled Crossover Trial Comparing the Impact of Sham or Intranasal Tear Neurostimulation on Conjunctival Goblet Cell Degranulation","volume":"177","author":"Gumus","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0014","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1113\/JP275100","article-title":"The dual-gate model for pentameric ligand-gated ion channels activation and desensitization","volume":"596","author":"Gielen","year":"2018","journal-title":"J Physiol"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1152\/physrev.00015.2008","article-title":"Mammalian nicotinic acetylcholine receptors: from structure to function","volume":"89","author":"Albuquerque","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0016","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bcp.2009.05.024","article-title":"Structural and functional diversity of native brain neuronal nicotinic receptors","volume":"78","author":"Gotti","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0017","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11154-020-09584-3","article-title":"Therapeutic potential of alpha7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation","volume":"21","author":"Xie","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0018","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/exd.14173","article-title":"Targeting the alpha7 nicotinic acetylcholine receptor-A novel road towards the future treatment of skin diseases","volume":"29","author":"Stegemann","year":"2020","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/7854_2020_141","article-title":"A Review of the Cholinergic System and Therapeutic Approaches to Treat Brain Disorders","volume":"45","author":"Bertrand","year":"2020","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108053","article-title":"Alpha7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future","volume":"170","author":"Terry","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0021","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17460441.2018.1458090","article-title":"Discovery and development of varenicline for smoking cessation","volume":"13","author":"Jordan","year":"2018","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0022","series-title":"Tyrvaya (varenicline solution) nasal spray","year":"2021"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0023","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1542-0124(12)70196-9","article-title":"Methodologies for the study of ocular surface disease","volume":"3","author":"Ousler","year":"2005","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0024","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40123-017-0110-x","article-title":"Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review","volume":"6","author":"Ousler","year":"2017","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0025","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","article-title":"Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial","volume":"129","author":"Wirta","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0026","article-title":"ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease","volume":"22","author":"Wirta","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0027","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1167\/iovs.16-20902","article-title":"Expression Profiling of Nonpolar Lipids in Meibum From Patients With Dry Eye: A Pilot Study","volume":"58","author":"Chen","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0028","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jtos.2020.03.003","article-title":"Infrared meibography allows detection of dimensional changes in meibomian glands following intranasal neurostimulation","volume":"18","author":"Pondelis","year":"2020","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0029","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtos.2018.11.009","article-title":"Characterization of tear production in subjects with dry eye disease during intranasal tear neurostimulation: Results from two pivotal clinical trials","volume":"17","author":"Sheppard","year":"2019","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0030","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7542929","article-title":"Review: The Lacrimal Gland and Its Role in Dry Eye","volume":"2016","author":"Conrady","year":"2016","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0031","doi-asserted-by":"crossref","first-page":"e79653","DOI":"10.1371\/journal.pone.0079653","article-title":"Acute activation, desensitization and smoldering activation of human acetylcholine receptors","volume":"8","author":"Campling","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2022.07.006_bib0032","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0022-3565(24)38184-4","article-title":"Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure","volume":"289","author":"Reitstetter","year":"1999","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:41Z","timestamp":1758963461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822002387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0149291822002387"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.07.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}